Company Overview - Guilin Sanjin Pharmaceutical Co., Ltd. is located in the Lingui District of Guilin City, Guangxi Zhuang Autonomous Region, established on February 23, 1994, and listed on July 10, 2009 [2] - The company specializes in the research, production, and sales of traditional Chinese medicine products, including throat and oral medications, anti-urinary tract infection drugs, and cardiovascular drugs, along with other natural medicines and biological preparations [2] - The main business revenue composition is as follows: Industrial 97.26%, Commodity circulation 2.37%, Other 0.38% [2] Stock Performance - As of September 23, the stock price of Guilin Sanjin fell by 2.11%, trading at 14.35 CNY per share, with a total market capitalization of 8.432 billion CNY [1] - Year-to-date, the stock price has decreased by 2.65%, with a 4.01% drop over the last five trading days and a 7.66% decline over the last 20 days [2] - The stock has appeared on the "Dragon and Tiger List" once this year, with the last appearance on January 7, where it recorded a net buy of -177.741 million CNY [2] Financial Performance - For the first half of 2025, Guilin Sanjin reported a revenue of 999.8 million CNY, a year-on-year decrease of 6.56%, and a net profit attributable to shareholders of 287 million CNY, down 4.70% year-on-year [3] - The company has distributed a total of 4.592 billion CNY in dividends since its A-share listing, with 1.175 billion CNY distributed over the last three years [4] Shareholder Information - As of September 10, the number of shareholders for Guilin Sanjin was 21,800, a decrease of 0.78% from the previous period, with an average of 25,628 circulating shares per shareholder, an increase of 0.78% [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 6.3037 million shares, an increase of 1.8371 million shares from the previous period [4] Market Position - Guilin Sanjin is classified under the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [2] - The company is associated with several concept sectors, including anti-influenza, traditional Chinese medicine, small-cap stocks, innovative drugs, and margin financing [2]

Core Viewpoint - Guilin Sanjin experienced a slight decline in stock price and trading volume on September 17, with a focus on financing and margin trading activities, indicating a mixed sentiment among investors [1][2]. Financing Summary - On September 17, Guilin Sanjin had a financing buy-in amount of 5.23 million yuan, with a net financing purchase of 1.048 million yuan after 4.18 million yuan was repaid [1]. - The total financing and margin trading balance reached 13.8 million yuan, with financing balance accounting for 1.57% of the circulating market value, indicating a high level compared to the past year [1]. - The company’s financing balance of 1.37 billion yuan is above the 80th percentile of the past year, suggesting strong investor interest [1]. Margin Trading Summary - On the same day, Guilin Sanjin repaid 1,900 shares in margin trading and sold 200 shares, with the selling amount calculated at 2,972 yuan [1]. - The margin trading balance stood at 175,300 yuan, which is below the 50th percentile of the past year, indicating a lower level of margin trading activity [1]. Company Overview - Guilin Sanjin Pharmaceutical Co., Ltd. was established on February 23, 1994, and listed on July 10, 2009, focusing on the research, production, and sales of traditional Chinese medicine products related to throat and oral medications, urinary tract infection treatments, and cardiovascular drugs [1]. - The company’s main business revenue composition is 97.26% from industrial operations, 2.37% from commodity circulation, and 0.38% from other sources [1]. Financial Performance - For the first half of 2025, Guilin Sanjin reported an operating income of 998 million yuan, a year-on-year decrease of 6.56%, and a net profit attributable to shareholders of 287 million yuan, down 4.70% year-on-year [2]. - The company has cumulatively distributed 4.592 billion yuan in dividends since its A-share listing, with 1.175 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 10, the number of shareholders for Guilin Sanjin was 21,800, a decrease of 0.78% from the previous period, while the average circulating shares per person increased by 0.78% to 25,628 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 6.3037 million shares, an increase of 1.8371 million shares from the previous period [3].